Patents Assigned to Celgene Corporation
  • Publication number: 20240327381
    Abstract: Provided herein are compounds and compositions thereof for degrading an engineered polypeptide in a cell. In some embodiments, the compounds and compositions are provided for treatment of cancer.
    Type: Application
    Filed: February 7, 2024
    Publication date: October 3, 2024
    Applicants: Celgene Corporation, Bristol-Myers Squibb Company
    Inventors: Laura Akullian D'Agostino, Godwin Kumi, Haibo Liu
  • Patent number: 12103920
    Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: October 1, 2024
    Assignee: Celgene Corporation
    Inventors: Matthew D. Alexander, Matthew D. Correa, Deepak Dalvie, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, III, Evan J. Horn, Dehua Huang, Christopher Mayne, Stephen Norris, Veronique Plantevin-Krenitsky, John J. Sapienza, Lida Tehrani, Brandon W. Whitefield
  • Patent number: 12103923
    Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: October 1, 2024
    Assignee: Celgene Corporation
    Inventors: Maria Soraya Carrancio Anton, Tonia J. Buchholz, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
  • Patent number: 12090147
    Abstract: Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1? blocker.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 17, 2024
    Assignee: Celgene Corporation
    Inventors: Tonia Buchholz, Jinhong Fan, Daniel W. Pierce, Michael Pourdehnad, Tsun-Wen Yao
  • Publication number: 20240299570
    Abstract: The present disclosure relates to methods of using antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs in combination with a gamma secretase inhibitor (GSI), such as in therapeutic methods. Also provided are pharmaceutical compositions and kits comprising the antibody conjugates and GSI.
    Type: Application
    Filed: January 30, 2024
    Publication date: September 12, 2024
    Applicant: CELGENE CORPORATION
    Inventor: Kaida WU
  • Patent number: 12084499
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to signal regulatory protein-? (SIRP?) and modulate the activity of SIRP?.
    Type: Grant
    Filed: February 1, 2023
    Date of Patent: September 10, 2024
    Assignee: Celgene Corporation
    Inventors: Mahan Abbasian, Henry H. Chan, Laure Escoubet, Gustavo Fenalti, Kandasamy Hariharan, Monica Wai Ling Leung, Konstantinos Mavrommatis, David P. Mikolon, Heather K. Raymon, Carlo Steven Santos, Jeonghoon Sun, Christina Valerie Trout
  • Patent number: 12065423
    Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate are also disclosed.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: August 20, 2024
    Assignee: Celgene Corporation
    Inventor: Jerry Lee Atwood
  • Patent number: 12064437
    Abstract: A method of determining a dose of a treatment compound for treating a subject having systemic lupus erythematosus (SLE), comprising obtaining a sample from the subject and measuring the gene expression level of IKZF3 and/or the gene expression levels of IFI27, IFI44, IFI44L, and RSAD2 in the sample.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: August 20, 2024
    Assignee: CELGENE CORPORATION
    Inventors: Peter H. Schafer, Shaojun Tang
  • Patent number: 12064427
    Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.
    Type: Grant
    Filed: August 30, 2023
    Date of Patent: August 20, 2024
    Assignee: Celgene Corporation
    Inventors: Anjali Agrawal, Ming J. Chen, Shyam Babu Karki, Prajwal Gunwanth Thool, Dora Visky, Ruimin Xie
  • Publication number: 20240270714
    Abstract: Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.
    Type: Application
    Filed: January 25, 2024
    Publication date: August 15, 2024
    Applicant: Celgene Corporation
    Inventors: Jeffrey M. Schkeryantz, Karin Worm, Rulin Ma, Patrick W. Papa
  • Patent number: 12053466
    Abstract: Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) provided herein, in treating, preventing or managing multiple myeloma.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: August 6, 2024
    Assignee: Celgene Corporation
    Inventors: Daniel W. Pierce, Lilly L. Wong
  • Patent number: 12053482
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Grant
    Filed: April 24, 2023
    Date of Patent: August 6, 2024
    Assignee: CELGENE CORPORATION
    Inventors: Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • Patent number: 12049470
    Abstract: The present disclosure provides novel synthetic intermediates useful in the synthesis of MK2 kinase inhibitors.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: July 30, 2024
    Assignee: Celgene Corporation
    Inventors: Alexander L. Ruchelman, John R. Coombs, Keming Zhu, Daniel Lim, Candice Lee Joe, David T. George, Bin Zheng, Dong Lin
  • Publication number: 20240228667
    Abstract: Provided herein are methods of treating multiple myeloma, comprising administering to a subject with multiple myeloma an inhibitor of Nuclear Receptor Binding SET Domain Protein 2 (NSD2). Also provided are methods of use wherein the multiple myeloma has previously been determined to have a 4:14 chromosome translocation (t(4;14)).
    Type: Application
    Filed: February 25, 2022
    Publication date: July 11, 2024
    Applicant: Celgene Corporation
    Inventors: Nicholas Stong, Patrick R. Hagner, William Edward Pierceall, Anjan Thakurta, Jennifer Erin Flynt, Maria Ortiz-Estevez
  • Patent number: 12029738
    Abstract: Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
    Type: Grant
    Filed: November 8, 2021
    Date of Patent: July 9, 2024
    Assignee: Celgene Corporation
    Inventors: Matthew D. Alexander, Gerald D. Artman, Gordon L. Bray, James Carmichael, Soraya Carrancio, Brian E. Cathers, Matthew D. Correa, Joshua Hansen, Courtney G. Havens, Timothy S. Kercher, Antonia Lopez-Girona, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Rama K. Narla, Joseph R. Piccotti, Daniel W. Pierce, Paula A. Tavares-Greco, Brandon W. Whitefield, Lilly L. Wong, Nanfei Zou
  • Publication number: 20240207310
    Abstract: Provided herein are methods, compositions, and uses for treating subjects with diseases and conditions, such as those involving or associated with B cell maturation antigen (BCMA). In some aspects, the present disclosure relates to certain combination therapies that include administration of a cell therapy, such as a BCMA-targeted T cell therapy, in combination with immunomodulatory agents and other agents, such as dexamethasone, including for the treatment of subjects with multiple myeloma. In some embodiments, the multiple myeloma is a relapsed or refractory multiple myeloma.
    Type: Application
    Filed: April 15, 2022
    Publication date: June 27, 2024
    Applicant: Celgene Corporation
    Inventors: Julie Ann RYTLEWSKI, Gianfranco PITTARI
  • Publication number: 20240132623
    Abstract: Provided herein are methods of treating multiple myeloma, comprising administering to a subject with multiple myeloma an inhibitor of Nuclear Receptor Binding SET Domain Protein 2 (NSD2). Also provided are methods of use wherein the multiple myeloma has previously been determined to have a 4:14 chromosome translocation (t(4;14)).
    Type: Application
    Filed: February 25, 2022
    Publication date: April 25, 2024
    Applicant: Celgene Corporation
    Inventors: Nicholas Stong, Patrick R. Hagner, William Edward Pierceall, Anjan Thakurta, Jennifer Erin Flynt, Maria Ortiz-Estevez
  • Patent number: 11963520
    Abstract: Provided are transgenic mice whose genome comprises a nucleic acid sequence encoding human cereblon (CRBN) or a fragment thereof, wherein endogenous mouse CRBN is not expressed in the transgenic mice. Also provided are cells, cell lines, tissues, and organs derivable from the transgenic mice, and methods for producing and using such mice.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: April 23, 2024
    Assignee: CELGENE CORPORATION
    Inventors: Rajesh Chopra, Anke Klippel
  • Publication number: 20240124444
    Abstract: Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, R3, R4 and R5 are as defined herein (referred to herein as “Heterocyclic Compounds”), compositions comprising an effective amount of a Heterocyclic Compound, as well as methods of preventing and/or treating cryptosporidiosis and/or inhibiting a parasite or parasitic activity.
    Type: Application
    Filed: December 27, 2021
    Publication date: April 18, 2024
    Applicant: Celgene Corporation
    Inventors: Dale E. Robinson, Natalie Hawryluk, Stacie Canan
  • Publication number: 20240124394
    Abstract: Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 18, 2024
    Applicant: Celgene Corporation
    Inventors: Jeffrey M. Schkeryantz, Julie Selkirk, Philip Stewart Turnbull, Junko Tamiya, Patrick W. Papa, Jean-Francois Brazeau, Karin Worm